ClinicalTrials.gov
public full text
Public Domain
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug Rebif®.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis#801703
- Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study#337511
- Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications.#214191
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis#1151942
- Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses#883943
Record · ID 1396717
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive